This promotional website is for UK healthcare professionals involved in the care of patients with cancer. Adverse event reporting information can be found below.
VENCLYXTO® in Acute Myeloid Leukaemia (AML)
Indicated in combination with a hypomethylating agent or low-dose cytarabine for the treatment of adult patients with newly diagnosed AML who are ineligible for intensive chemotherapy1
Explore Venclyxto data and resources
View on-demand content
View and download resources
Fill in a form to make an appointment with a representative
VENCLYXTO® in Acute Myeloid Leukaemia (AML)
Indicated in combination with a hypomethylating agent or low-dose cytarabine for the treatment of adult patients with newly diagnosed AML who are ineligible for intensive chemotherapy1
Explore Venclyxto data and resources
View on-demand content
View and download resources
Fill in a form to make an appointment with a representative
References
- VENCLYXTO Summary of Product Characteristics.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores.
Adverse events should also be reported to AbbVie on GBPV@abbvie.com
UK-VNCAML-240186. Date of preparation: November 2024.
